Mitral valve replacement

Mitral valve replacement is a procedure whereby the diseased mitral valve of a patient's heart is replaced by either a mechanical or tissue (bioprosthetic) valve.

Mitral valve replacement
ICD-9-CM35.23-35.24

The mitral valve may need to be replaced because:

  • The valve is leaky (mitral valve regurgitation)
  • The valve is narrowed and doesn't open properly (mitral valve stenosis)

Causes of mitral valve disease include infection, calcification and inherited collagen disease. Current mitral valve replacement approaches include open heart surgery and minimally invasive cardiac surgery (MICS).

Normal mitral valve anatomy and physiology

The mitral valve is a bileaflet valve sited between the left atrium and left ventricle, responsible for preventing blood flowing from the atrium to the ventricle when the heart contracts. It is elliptical, and its area varies from 5.0 to 11.4 cm2. The valve leaflets are separated by two commissures, and each leaflet of the valve (anterior leaflet, the large one, and posterior leaflet, the small one) has three sections (p1, p2, p3). Histologically, each leaflet is composed of the solid fibrosa, the spongiosa at the atrial surface and another fibroelastic layer covering the leaflets.[1] Two papillary muscles originating from the base of the left ventricle hold the mitral leaflets in place through chordae tendinae, which insert the edge of the leaflets, preventing them from leaking during left ventricle systole.[2]

Mitral stenosis and regurgitation

The most common cause of mitral stenosis is rheumatic fever, seen mostly in the developing world. Other causes are mitral degenerative disease, severe calcification (elderly), congenital deformities, malignant carcinoid syndrome, neoplasm, left atrial appendage thrombus, endocarditic vegetations, certain inherited metabolic diseases, or complications of previous procedures at the aortic valve.[3] Mitral stenosis causes left atrial pressure to increase, which, if left untreated, can lead to ventricular dilation, hypertrophy, atrial fibrillation, and thrombus creation. Symptoms include shortness of breath (dyspnea) on exertion, when lying flat (orthopnea) or during the night (paroxysmal nocturnal dyspnea), and fatigue.[4]

If mitral leaflets don't coapt (close) effectively, blood flows backwards (regurgitation) from the left ventricle towards the left atrium during systole. The most common causes are myxomatous degeneration (Barlow disease), ischemic heart disease, dilated cardiomyopathy, rheumatic valve disease, mitral annular calcification, infective endocarditis, congenital anomalies, endocardial fibrosis, myocarditis, and collagen-vascular disorders.[5] The most used system to classify mitral valve regurgitation is Carpentier's classification, which separates mitral regurgitation into three types, depending on the leaflet motion in relation to the mitral annular plane:

  • Type I: the leaflets are moving normally
  • Type II: leaflet motion is excessive
  • Type III: leaflet movement is restricted.[5]

Artificial valve types

There are two main types of artificial mitral valve: mechanical valves and tissue (bioprosthetic) valves.[6] They come in various sizes (commonly starting from an external diameter of 19 mm and increasing by 2 mm per model).[7]

Mechanical valves

Mechanical valves are made from metal and/or pyrolitic carbon,[8] and can last 20–30 years.[9] The risk of blood clots forming is higher with mechanical valves than with bioprosthetic valves. As a result, patients with mechanical valves must take blood-thinning medication (anticoagulants) for the rest of their lives, making them more prone to bleeding.[9]

There are three types of mechanical valves:

  1. Caged ball valve (not in use any more)
  2. Tilting disc
  3. Bileaflet disc

Bileaflet valves are the most common type of mechanical valve, offering desirable haemodynamics.[10] The two leaflets of a bileaflet disc valve open during diastole and close during systole.

Bioprosthetic valves

Bioprosthetic valves are made from animal tissues. Most people with bioprosthetic valves don’t need to take anticoagulants long term. However, bioprosthetic valves may only last 10–15 years.[9] They tend to deteriorate more quickly in younger patients.[9] Valve failure prevalence at 10 years is 30%, increasing to 35–65% at 15 years.[11] New tissue preservation technologies are being studied to try to increase the durability of bioprosthetic valves.[12]

Valve selection

The choice of valve depends upon the patient's age, medical condition, preferences, and lifestyle.[9] Typically, patients younger than 65 years old will receive a mechanical valve unless they are unable to take long-term anticoagulation, and patients older than 70 years will receive a bioprosthetic valve.[6]

Procedure

The most common approach for surgeons to reach the heart is a median sternotomy (vertically cutting the breastbone), but other incisions can be employed, such as a left or right thoracotomy.[13] After the heart is exposed, the patient is put on a cardiopulmonary bypass machine, also known as a heart–lung machine. This machine breathes for the patient and pumps their blood around their body – bypassing the heart – while the surgeon replaces the heart valve. Next, an aortic clamp is placed on the aorta, and the heart is stopped (cardioplegia).[13] Depending on the pathology of the mitral valve and surgeon's preference, various approaches can be used to access the mitral valve. The interatrial groove approach involves incising the left atrium posterior to the interatrial groove. The transatrial oblique approach is utilized when the left atrium is small. In this approach, the right atrium is opened and another incision is made at the interatrial septum.[14]

The valve is excised 4–5 mm from the annulus, leaving intact the attached chordae unless they are calcified or otherwise diseased. The valve is replaced by a mechanical or bioprosthetic valve. The replacement valve is sewn into the annulus with interrupted or horizontal mattress sutures with the pledgets on the atrial side.[15] The atrial walls are closed, taking care not to trap air within the chambers of the heart.[16] The heart is restarted, and the patient is taken off the heart–lung machine.

Recovery

Following surgery, patients are typically taken to an intensive care unit for monitoring. They may need a respirator to help them breathe for the first few hours or days after surgery. The patient should be able to sit up in bed within 24 hours. After two days, the patient may be moved out of the intensive care unit. Patients are usually discharged after 7–10 days. If the mitral valve replacement is successful, patients can expect their symptoms to improve significantly.[17]

Some scarring occurs after surgery. After median sternotomy, the patient will have a vertical scar on their chest above their breastbone. If the heart is accessed from under the left breast there will be a smaller scar in this location.[18]

Patients with a bioprosthetic mitral valve are prescribed anticoagulants, such as warfarin, for 6 weeks to 3 months after their operation, while patients with mechanical valves are prescribed anticoagulants for the rest of their lives. Anticoagulants are taken to prevent blood clots, which can move to other parts of the body and cause serious medical problems, such as a heart attack. Anticoagulants will not dissolve a blood clot but they do prevent other clots from forming or prevent clots from becoming larger.[19]

Once their wounds have healed, patients should have few, if any, restrictions from daily activities. People are advised to walk or undertake other physical activities gradually to regain strength. Patients who have physically demanding jobs will have to wait a little longer than those who don’t. Patients are also restricted from driving a car for six weeks after the surgery.

Complications

As with other cardiac procedures, mitral valve replacement is associated with risks, such as bleeding, infection, thromboembolism, renal shutdown, cardiac tamponade, stroke, or reaction to anesthesia.[20] The risk of death is about 1%.[21] Risks depend on a patient’s age, general health, specific medical conditions, and heart function.[22]

Minimally invasive mitral valve replacement

Since the 1990s, surgeons have been working on less invasive approaches to mitral valve surgery, known as minimally invasive cardiac surgery (MICS). Minimally invasive mitral valve replacement involves a small incision (5–8 cm) just below the right breast. The benefits of MICS over conventional surgery include reduced hospital stay and blood transfusion requirements, and a smaller scar.[23]

Transcatheter mitral valve replacement

Rather than removing the existing valve, transcatheter mitral valve replacement[24] involves wedging a new valve into the site of the existing valve. The replacement valve is delivered to the site of the existing valve through a tube called a catheter. The catheter may be inserted through the femoral artery in the thigh, or through a small incision in the chest.[25] Once the replacement valve is in place, it is expanded, pushing the old valve’s leaflets (the sections that open and close) out of the way.

Transcatheter mitral valves are still being studied in clinical trials; none are commercially available.

Alternatives to mitral valve replacement

Repair
Main article: Mitral valve repair

Many mitral valves can be repaired instead of replaced. In fact, mitral valve repair is recommended by international guidelines wherever possible.[26][27] Advantages of mitral valve repair over replacement include lower surgical mortality (~1% for repair vs ~5% for replacement[28]), lower rates of stroke and endocarditis (an infection of the heart’s inner lining), equivalent or better long‑term durability,[29][30][31] and improved long-term survival.[29] Patients who have their valve repaired have a similar life expectancy to the general population.[32] In addition, patients may not need to take anticoagulants long term following mitral valve repair.[33]

Non-surgical options

For individuals with few symptoms, or those with contraindications to surgery, options exist for medical treatment in both mitral insufficiency and mitral valve stenosis, although they won't cure the conditions. Such medical treatments include diuretics,[34][35] vasodilators,[35][34] and ACE inhibitors.[34][36][37]

gollark: Install the*POTATO OPERATION SYSTEM*immediately!!!
gollark: No, my code was wrong.
gollark: ++exec -L python```import randomprint(random.choice(["TempleOS", "PotatOS"]))```
gollark: ...
gollark: ++exec -L python```import randomprint(random.choice(["TempleOS", "PotatOS"])```

See also

References
  1. Fann, Ingels & Miller 2017, p. 761.
  2. Fann, Ingels & Miller 2017, p. 784.
  3. Fann, Ingels & Miller 2017, p. 764.
  4. Fann, Ingels & Miller 2017, p. 767.
  5. Fann, Ingels & Miller 2017, p. 770.
  6. van der Merwe, J (2017). "Mitral Valve Replacement-Current and Future Perspectives". Open Journal of Cardiovascular Surgery. 9: 1179065217719023. doi:10.1177/1179065217719023. PMC 5513524. PMID 28757798.
  7. Kouchoukos et al. 2013, pp. 518-19.
  8. Gott, VL (2003). "Mechanical heart valves: 50 years of evolution". The Annals of Thoracic Surgery. 76 (6): S2230-9. doi:10.1016/j.athoracsur.2003.09.002. PMID 14667692.
  9. Tillquist, MN (2011). "Cardiac crossroads: deciding between mechanical or bioprosthetic heart valve replacement". Patient Preference and Adherence. 5: 91–9. doi:10.2147/PPA.S16420. PMC 3063655. PMID 21448466.
  10. Khalili, Fardin; Gamage, Peshala P. T.; Sandler, Richard H.; Mansy, Hansen A. (2018-09-16). "Adverse Hemodynamic Conditions Associated with Mechanical Heart Valve Leaflet Immobility". Bioengineering. 5 (3): 74. doi:10.3390/bioengineering5030074. ISSN 2306-5354. PMC 6165326. PMID 30223603.
  11. Kouchoukos et al. 2013, pp. 519-20.
  12. Flameng, Willem; Hermans, Hadewich; Verbeken, Erik; Meuris, Bart (2015). "A randomized assessment of an advanced tissue preservation technology in the juvenile sheep model". The Journal of Thoracic and Cardiovascular Surgery. 149 (1): 340–345. doi:10.1016/j.jtcvs.2014.09.062. ISSN 0022-5223. PMID 25439467.
  13. Khonsari & Sintek 2003, p. 81.
  14. Khonsari & Sintek 2003, pp. 82-83.
  15. Kouchoukos et al. 2013, pp. 492-493.
  16. Khonsari & Sintek 2003, pp. 92-88.
  17. NHS (2017-10-18). "Mitral valve problems". NHS. Retrieved 6 June 2019.
  18. "Mitral Valve Repair/Replacement". Baylor College of Medicine. Retrieved 18 February 2012.
  19. "Deep vein thrombosis - Treatment". nhs.uk. 2017-11-16. Retrieved 2019-07-29.
  20. Kouchoukos et al. 2013, pp. 189 & 503.
  21. Kouchoukos et al. 2013, pp. 504.
  22. HealthLinkBC. "Mitral Valve Replacement Surgery". HealthLinkBC. Retrieved 6 June 2019.
  23. Ramlawi, Basel; Gammie, James S. (2016). "Mitral Valve Surgery: Current Minimally Invasive and Transcatheter Options". Methodist DeBakey Cardiovascular Journal. 12 (1): 20–26. doi:10.14797/mdcj-12-1-20. ISSN 1947-6094. PMC 4847963. PMID 27127558.
  24. Alkhouli, Mohamad; Alqahtani, Fahad; Aljohani, Sami (2017). "Transcatheter mitral valve replacement: an evolution of a revolution". Journal of Thoracic Disease. 9 (S7): S668–S672. doi:10.21037/jtd.2017.05.60. PMC 5505942. PMID 28740722.
  25. "Transcatheter Mitral Valve Replacement - TMVR Explained • MyHeart". MyHeart. 2017-12-27. Retrieved 2019-07-29.
  26. Baumgartner, Helmut; Falk, Volkmar; Bax, Jeroen J; De Bonis, Michele; Hamm, Christian; Holm, Per Johan; Iung, Bernard; Lancellotti, Patrizio; Lansac, Emmanuel (2017-09-21). "2017 ESC/EACTS Guidelines for the management of valvular heart disease". European Heart Journal. 38 (36): 2739–2791. doi:10.1093/eurheartj/ehx391. ISSN 0195-668X. PMID 28886619.
  27. Nishimura, Rick A.; Otto, Catherine M.; Bonow, Robert O.; Carabello, Blase A.; Erwin, John P.; Fleisher, Lee A.; Jneid, Hani; Mack, Michael J.; McLeod, Christopher J. (July 2017). "2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease". Journal of the American College of Cardiology. 70 (2): 252–289. doi:10.1016/j.jacc.2017.03.011. PMID 28315732.
  28. Society of Thoracic Surgeons. "Adult Cardiac Surgery Executive Summary - Harvest 4 2018" (PDF). Retrieved 29 July 2019.
  29. Daneshmand, Mani A.; Milano, Carmelo A.; Rankin, J. Scott; Honeycutt, Emily F.; Swaminathan, Madhav; Shaw, Linda K.; Smith, Peter K.; Glower, Donald D. (2009). "Mitral Valve Repair for Degenerative Disease: A 20-Year Experience". The Annals of Thoracic Surgery. 88 (6): 1828–1837. doi:10.1016/j.athoracsur.2009.08.008. PMID 19932244.
  30. Gillinov, A. Marc; Blackstone, Eugene H.; Nowicki, Edward R.; Slisatkorn, Worawong; Al-Dossari, Ghannam; Johnston, Douglas R.; George, Kristopher M.; Houghtaling, Penny L.; Griffin, Brian (2008). "Valve repair versus valve replacement for degenerative mitral valve disease". The Journal of Thoracic and Cardiovascular Surgery. 135 (4): 885–893.e2. doi:10.1016/j.jtcvs.2007.11.039. PMID 18374775.
  31. Mohty, D.; Orszulak, T.A.; Schaff, H.V. (2001). "Very long-term survival and durability of mitral valve repair for mitral valve prolapse". ACC Current Journal Review. 11 (2): 78. doi:10.1016/s1062-1458(02)00576-7. ISSN 1062-1458.
  32. Vassileva, Christina M.; Mishkel, Gregory; McNeely, Christian; Boley, Theresa; Markwell, Stephen; Scaife, Steven; Hazelrigg, Stephen (2013-05-07). "Long-Term Survival of Patients Undergoing Mitral Valve Repair and Replacement: A Longitudinal Analysis of Medicare Fee-for-Service Beneficiaries". Circulation. 127 (18): 1870–1876. doi:10.1161/CIRCULATIONAHA.113.002200. ISSN 0009-7322. PMID 23569153.
  33. Moss, R. R. (2003-09-09). "Outcome of Mitral Valve Repair or Replacement: A Comparison by Propensity Score Analysis". Circulation. 108 (90101): 90II––97. doi:10.1161/01.cir.0000089182.44963.bb. ISSN 0009-7322. PMID 12970215.
  34. VOC=VITIUM ORGANICUM CORDIS, a compendium of the Department of Cardiology at Uppsala Academic Hospital. By Per Kvidal September 1999, with revision by Erik Björklund May 2008
  35. Elizabeth D Agabegi; Agabegi, Steven S. (2008). Step-Up to Medicine (Step-Up Series). Hagerstwon, MD: Lippincott Williams & Wilkins. ISBN 978-0-7817-7153-5. Chapter 1: Diseases of the Cardiovascular system > Section: Valvular Heart Disease
  36. Greenberg BH, Massie BM, Brundage BH, Botvinick EH, Parmley WW, Chatterjee K (1978). "Beneficial effects of hydralazine in severe mitral regurgitation". Circulation. 58 (2): 273–9. doi:10.1161/01.cir.58.2.273. PMID 668075.
  37. Hoit BD (1991). "Medical treatment of valvular heart disease". Curr. Opin. Cardiol. 6 (2): 207–11. doi:10.1097/00001573-199104000-00005. PMID 10149580.

Sources
  • Fann, James I; Ingels, Neil B.; Miller, D. Craig (28 August 2017). "Pathophysiology of Mitral Valve Disease". In Lawrence H. Cohn; David H. Adams (eds.). Cardiac Surgery in the Adult Fifth Edition. McGraw-Hill Education. ISBN 978-0-07-184487-1.CS1 maint: ref=harv (link)
  • Khonsari, Siavosh; Sintek, Colleen Flint (2003). Cardiac Surgery, Safeguards and Pitfalls in Operative Techniques, 3rd edition. Lippincott Williams & Wilkins. ISBN 978-0781735407.CS1 maint: ref=harv (link)
  • Kouchoukos, Nicholas; Blackstone, Eugene; Hanley, Frank; Kirklin, James K. (2013). Cardiac Surgery. Elsevier Health Sciences. ISBN 9781416063919.CS1 maint: ref=harv (link)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.